微生物同定の市場規模：製品タイプ別、用途別、方法別、地域別、2024年～2031年

微生物同定市場の評価、2024年～2031年

微生物同定市場は、ヘルスケア、製薬、食品安全など様々な分野における微生物検出、同定、規制遵守の進化する基準を満たすための先進技術の採用により、著しい成長を遂げています。迅速な病原体検出やゲノム配列決定からコンプライアンス・モニタリングや品質管理まで幅広い用途で、微生物同定ソリューションは多様な業務ニーズに対応する上で重要な役割を果たしています。2024年に50億3,000万米ドルと評価されたこの市場は、2031年までにおよそ116億9,000万米ドルに達すると予測され、その力強い成長軌道を裏付けています。

堅牢な微生物同定とコンプライアンス・ソリューションの需要は、同定技術とシステム統合の進歩を促進しています。これらの技術革新は、リアルタイム病原体分析や適応検出制御などの自動化されたインテリジェント・システムとのシームレスな統合を可能にし、それによって業務効率を高め、規制遵守を保証します。このような統合により、微生物同定市場は2024年から2031年までCAGR12.27％を達成すると予想され、市場の成長を後押しする態勢が整っています。

微生物同定- 定義／概要

微生物同定は、ゲノム配列決定、生化学検査、質量分析などの方法を用いて、サンプル中の微生物の種と特徴を特定することを含みます。この方法は、ヘルスケア、医薬品、食品安全、および環境モニタリングでの使用に不可欠です。

微生物同定の用途には、ヘルスケアにおける病気の検出、医薬品における製品の安全性の保証、食品安全における汚染のモニタリング、環境衛生の評価などが含まれます。これらの用途は公衆衛生、規制遵守、製品および環境の品質向上に貢献します。

微生物同定の将来的な要素としては、自動化の進展、迅速な分析のための人工知能の利用、携帯可能なポイント・オブ・ケア機器の開発などが挙げられます。このような開発は、幅広いビジネスにおける微生物検査のスピード、精度、アクセシビリティを向上させ、ヘルスケアやそれ以外の分野での技術革新に拍車をかけることを目的としています。

ヘルスケア支出の増加はどのように微生物同定市場を促進するか？

ヘルスケア支出の増加は、病院が患者の転帰と感染制御を改善するために診断技術の改善に投資するため、微生物同定市場を促進します。資金提供の増加は、病原体の検出と治療精度を向上させる新しい微生物同定法の研究と開発を奨励しています。

さらに、世界のヘルスケアコストの上昇が、病院、診療所、診断研究所における微生物同定システムの必要性を高めています。これらの投資は、抗生物質耐性を防止し、タイムリーな疾病管理を保証し、ヘルスケア関連感染に対する高い規制基準を満たすために不可欠です。

さらに、ヘルスケア・システムが予防医療と個別化医療にシフトするにつれて、正確な微生物同定は治療戦略を個別化し、治療成果を最適化する上でますます重要になっています。このような精密医療への注目は、世界中の臨床現場における改良型微生物同定技術の継続的な革新と実装を後押ししています。

高い機器コストは微生物同定市場の妨げになるか？

高い機器価格が微生物同定分野の障害となり、小規模なヘルスケア施設やラボのアクセスを制限しています。予算制限により革新的技術の採用が阻害される可能性があり、財源やインフラが限られた地域での市場成長が抑制されます。

継続的な技術改良により、微生物検出装置のコストは徐々に低下し、効率は向上しています。小型化、自動化、クラウドベースのソリューションなどの革新は、診断能力を向上させながら運用コストの削減を約束します。このような改善は、特に新興経済国や資源に制約のある状況において、障壁を減らし、市場の可能性を広げます。

業界参加者間の戦略的提携と協力は、費用対効果の高いソリューションを可能にし、微生物同定技術の値ごろ感を高める。研究開発におけるコラボレーションはイノベーションを促進し、先進的な診断技術をより身近で実用的なものとすることで、世界中のより多様なヘルスケアプロバイダーが利用できるようになります。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 微生物同定市場：製品タイプ別

• 器具
• 消耗品
• ソフトウェア
• サービス

第5章 微生物同定市場：用途別

• 臨床診断
• 飲食品検査
• 製薬およびバイオテクノロジー用途
• 環境用途
• 研究用途

第6章 微生物同定市場：方法別

• 表現型法
• 遺伝子型法
• プロテオミクス法

第7章 地域分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Becton Dickinson and Company
• bioMerieux SA
• Shimadzu Corporation
• Thermo Fisher Scientific Inc
• Danaher Corporation
• Bruker Corporation
• QIAGEN N.V.
• Avantor, Inc.
• Biolog, Inc.

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Microbial Identification Market Valuation - 2024-2031

The microbial identification market is witnessing significant growth fueled by the adoption of advanced technologies to meet evolving standards in microbial detection, identification, and regulatory compliance across various sectors including healthcare, pharmaceuticals, and food safety. With applications ranging from rapid pathogen detection and genomic sequencing to compliance monitoring and quality control, microbial identification solutions play a crucial role in addressing diverse operational needs. Valued at USD 5.03 billion in 2024, the market is projected to reach approximatelyUSD 11.69 billion by 2031,underscoring its robust growth trajectory.

The demand for robust microbial identification and compliance solutions is driving advancements in identification technologies and system integration. These innovations enable seamless integration with automated and intelligent systems such as real-time pathogen analysis and adaptive detection controls, thereby enhancing operational efficiency and ensuring regulatory adherence. This integration is poised to bolster market growth with the microbial identification market expected to achieve a compound annual growth rate (CAGR) of 12.27% from 2024 to 2031.

Microbial Identification - Definition/ Overview

Microbial identification entails identifying the species and features of microorganisms in a sample using methods such as genomic sequencing, biochemical testing, and mass spectrometry. This method is critical for use in healthcare, pharmaceuticals, food safety, and environmental monitoring.

Microbial identification uses include detecting illnesses in healthcare assuring product safety in medicines, monitoring contamination in food safety, and evaluating environmental health. These applications contribute to public health, regulatory compliance, and the improvement of product and environmental quality.

Future elements of microbial identification include increased automation, the use of artificial intelligence for quick analysis, and the creation of portable, point-of-care devices. These developments aim to increase the speed, accuracy, and accessibility of microbiological testing across a wide range of businesses hence spurring innovation in healthcare and beyond.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How Growing Healthcare Spending Drive the Microbial Identification Market?

Growing healthcare spending propels the microbial identification market as hospitals invest in improved diagnostic techniques to better patient outcomes and infection control. Increased funding encourages the study and development of novel microbial identification methods which improves pathogen detection and treatment accuracy.

Furthermore, rising worldwide healthcare costs drive need for microbiological identification systems in hospitals, clinics, and diagnostic laboratories. These investments are critical for preventing antibiotic resistance ensuring timely illness management, and satisfying high regulatory standards for healthcare-associated infections.

Furthermore, as healthcare systems shift towards preventive care and personalised medicine, precise microbial identification becomes increasingly important in personalising treatment strategies and optimising therapeutic outcomes. This focus on precision healthcare drives continued innovation and implementation of improved microbial identification technology in clinical settings globally.

Will High Instrument Cost Hamper the Microbial Identification Market?

High instrument prices offer an obstacle to the microbiological identification sector limiting access for smaller healthcare facilities and laboratories. Budget limits may inhibit the adoption of innovative technology reducing market growth in areas with limited financial resources and infrastructure.

Ongoing technical improvements are gradually lowering costs and increasing the efficiency of microbiological detection devices. Innovations such as miniaturisation, automation, and cloud-based solutions promise to reduce operational costs while improving diagnostic capabilities. These improvements reduce barriers and broaden market potential especially in emerging economies and resource-constrained contexts.

Strategic alliances and collaborations among industry participants enable cost-effective solutions and increase the affordability of microbial identification technology. Collaboration in research and development fuels innovation making advanced diagnostic technologies more accessible and practical for a greater variety of healthcare providers around the world.

Category-Wise Acumens

Will Direct Microbial Detection Drive the Product Type Segment?

Instruments dominate the market. Direct microbial detection is expected to fuel expansion in the product type segment because it enables real-time identification and characterization of microbes without the requirement for culture-based approaches. This capacity improves diagnosis speed and accuracy which are critical for rapid response in hospital settings and infectious disease management.

Advances in direct detection methods such as molecular assays and mass spectrometry allow for the sensitive and specific identification of pathogens directly from clinical samples. These technologies shorten turnaround times improve treatment decisions, and reduce the hazards associated with delayed diagnosis resulting in their widespread use across healthcare facilities worldwide.

Furthermore, the trend towards personalised treatment and precision healthcare strengthens the demand for direct microbial detection technologies. These techniques provide individualised treatment regimens based on individual microbial profiles which drives innovation and investment.

Will Need for Rapid and Accurate Identification of Pathogens Drive the Application Segment?

Clinical Diagnostics dominate the market. The necessity for speedy and accurate pathogen identification is a major driver in the method segment which focuses on techniques such as molecular assays and mass spectrometry. These approaches provide short turnaround times and high specificity which is critical for accurate diagnosis and treatment in clinical diagnostics and healthcare settings.

Advances in molecular biology and genomic sequencing have transformed pathogen identification allowing for the targeted detection of microbial DNA and RNA from a wide range of clinical samples. These technologies give clinicians actionable insights into infectious diseases allowing them to make more educated therapeutic decisions and implement infection control measures.

Furthermore, the trend towards personalised treatment and precision healthcare increases the requirement for advanced pathogen detection technologies. Tailored treatment strategies based on exact microbiological profiling require reliable and rapid diagnostic tools putting novel technologies at the forefront.

Country/Region Wise Acumens

How Growing Need for Improving the Quality of Food Drive the Microbial Identification Market in North America Region?

North America dominates the microbial identification market. The growing requirement to improve food quality in North America propels the microbial identification market by guaranteeing safety and adherence to strict regulatory criteria. Robust microbial identification technologies enable the rapid detection of hazardous pathogens hence promoting effective food safety measures and protecting public health.

As customers seek safer and higher-quality food items, regulatory bodies impose strict requirements requiring extensive microbiological testing throughout the food supply chain. This requires the use of modern identification technologies like PCR and mass spectrometry to reliably detect pathogens and avoid foodborne diseases.

Furthermore, developments in microbial identification technologies allow for faster and more precise detection of contaminants in food, increasing efficiency and lowering the risk of food recall. These advances support market growth by empowering food manufacturers and regulatory agencies.

Will Increasing Prevalence of Infectious Diseases Boost the Microbial Identification Market in Asia-Pacific?

The Asia-Pacific region is the fastest-growing region in the microbial identification market. The rising frequency of infectious disorders in Asia-Pacific is likely to drive the microbial identification market. Advanced technologies like as molecular assays and quick diagnostic tests are critical in precisely detecting pathogens allowing for timely treatment and successful management of infectious diseases throughout the region.

Rapid urbanisation and changing lifestyles contribute to the development of infectious illnesses in Asia-Pacific necessitating the urgent need for accurate diagnostic techniques to control outbreaks and reduce public health hazards. Governments and healthcare providers are prioritising investments in microbial identification technologies to improve illness surveillance, track epidemiological trends, and carry out targeted therapies.

Furthermore, increased healthcare spending and measures to improve healthcare infrastructure increase demand for microbial identification systems. These technologies play an important role in enhancing diagnostic accuracy and assisting healthcare.

Competitive Landscape

The Microbial Identification Market is a dynamic and competitive industry, marked by a diverse array of players striving to capture market share. These companies are actively engaged in efforts to solidify their presence by implementing strategic initiatives such as collaborations, mergers, acquisitions, and garnering political support. With a focus on innovation, these organizations are continuously enhancing their product offerings to meet the diverse needs of consumers across various regions.

Some prominent players in microbial identification market include:

Becton Dickinson and Company

bioMerieux SA

Shimadzu Corporation

Thermo Fisher Scientific Inc

Danaher Corporation

Bruker Corporation

QIAGEN N.V.

Avantor, Inc.

Biology, Inc.

Latest Developments

In April 2024, Israel Aerospace Industries (IAI) and Aerotor Unmanned Systems signed a Memorandum of Understanding (MoU) to collaborate on improving unmanned aircraft system technologies. IAI will use its expertise in aviation and unmanned platforms, while Aerotor will incorporate its Apus multicopter, which has a core heavy-fuel propulsion system and a variable pitch mechanism. This combination enhances the Apus with increased payload capacity, endurance, and agility.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Microbial Identification Market, By Product Type

• Instruments
• Consumables
• Software
• Services

5. Microbial Identification Market, By Application

• Clinical diagnostics
• Food and beverage testing
• Pharmaceutical and biotechnology applications
• Environmental applications
• Research applications

6. Microbial Identification Market, By Method

• Phenotypic methods
• Genotypic methods
• Proteomic methods

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Becton Dickinson and Company
• bioMerieux SA
• Shimadzu Corporation
• Thermo Fisher Scientific Inc
• Danaher Corporation
• Bruker Corporation
• QIAGEN N.V.
• Avantor, Inc.
• Biolog, Inc.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References